STUDIES ON XYLANASE PRODUCTION BY Aspergillus niger ON TOMATO POMACE MEDIUM

There is a need for locally produced xylanase because of its vast importance and high cost of importation. Xylanase is used for many industrial processes such as for baking, bleaching paper pulp, bioethanol production and juice clarification. This study was therefore carried out to examine the potentials of tomato pomace as part of the growth medium for xylanase production. The objectives are to identify the specific activities of xylanase from the basal salt medium and the tomato pomace medium and to determine the Partial Purification of xylanase obtained from tomato pomace medium inoculated with A.niger This study isolated xylanase from A. niger on tomato pomace medium. The xylanase was partially purified and characterized. A. niger was obtained from deteriorated banana (Musa acuminata) fruit. A 72-h-old culture of A. niger was employed as the inoculum. It was inoculated onto Tomato pomace medium and a basal salt. Xylanase production was carried out after four days at room temperature (27 oC). Xylanase activity was determined by measuring the released reducing sugar (xylose). The specific activities of xylanase from the basal salt medium and the tomato pomace medium were 3.6 U/mg and 2.0 U/mg respectively. Partial purification of xylanase was by Ammonium sulphate precipitation. Optimum substrate concentration of 0.5mg/ml and a purification fold of 4.3 were obtained. The Michael is Menten constant (Km) from the Line-weaver burk plot was approximately 0.50mg/ml. This study established appreciable activity of xylanase from the A. niger used. It is therefore a potential organism for the utilization of tomato waste for xylanase production

Occupational Stress-Related Sleep Anomaly in Frontline COVID-19 Health Workers: The Possible Underlying Mechanisms

COVID-19 is a highly contagious viral illness that has claimed millions of lives worldwide. Since its emergence, it has exerted a negative impact on many sectors globally without the exception of frontline COVID-19 healthcare providers. Specifically, in frontline COVID-19 healthcare workers, occupational stress-related sleep disorders such as insomnia and daytime somnolence have been extensively reported and were characterized by neuro-immunological changes. However, the possible mechanisms that underlie the sleep disorders have not been elucidated. The review was designed to highlight possible sleep mechanisms responsible for insomnia and daytime somnolence reported in frontline COVID-19 health workers. Available evidence shows that emotional perturbation, hypertension, chronobiological disruption and prolonged exposure to artificial light are among the events orchestrating occupational-stress-related sleep disorders in frontline COVID-19 healthcare workers. Anxiety-associated sleep anomaly is attributable to stimulation of the reticular activating system which occurs as a result of activation of noradrenergic fiber and sympatho-adrenal axis. Another mechanism includes depletion of hippocampal and brain glycogen by anxiety-induced activation of corticotropin releasing hormone (CRH)-secreting brain neurons and hypothalamic-corticotropic-adrenal cortex axis. Spontaneous discharge of noradrenergic fiber during basal state and changes in normal secretory rhythm of hypnosis-related chemical messengers may be responsible for hypertension- and chronobiological disruption-induced sleep disorders, respectively. Lastly, prolonged light exposure-induced suppression of melatonin secretion may elicit disruption of normal circadian sleep

Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study

BACKGROUND: Limited information is available for patients with breast cancer (BC) and coronavirus disease 2019 (COVID-19), especially among underrepresented racial/ethnic populations. METHODS: This is a COVID-19 and Cancer Consortium (CCC19) registry-based retrospective cohort study of females with active or history of BC and laboratory-confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection diagnosed between March 2020 and June 2021 in the US. Primary outcome was COVID-19 severity measured on a five-level ordinal scale, including none of the following complications, hospitalization, intensive care unit admission, mechanical ventilation, and all-cause mortality. Multivariable ordinal logistic regression model identified characteristics associated with COVID-19 severity. RESULTS: 1383 female patient records with BC and COVID-19 were included in the analysis, the median age was 61 years, and median follow-up was 90 days. Multivariable analysis revealed higher odds of COVID-19 severity for older age (aOR per decade, 1.48 [95% CI, 1.32-1.67]); Black patients (aOR 1.74; 95 CI 1.24-2.45), Asian Americans and Pacific Islander patients (aOR 3.40; 95 CI 1.70-6.79) and Other (aOR 2.97; 95 CI 1.71-5.17) racial/ethnic groups; worse ECOG performance status (ECOG PS ≥2: aOR, 7.78 [95% CI, 4.83-12.5]); pre-existing cardiovascular (aOR, 2.26 [95% CI, 1.63-3.15])/pulmonary comorbidities (aOR, 1.65 [95% CI, 1.20-2.29]); diabetes mellitus (aOR, 2.25 [95% CI, 1.66-3.04]); and active and progressing cancer (aOR, 12.5 [95% CI, 6.89-22.6]). Hispanic ethnicity, timing, and type of anti-cancer therapy modalities were not significantly associated with worse COVID-19 outcomes. The total all-cause mortality and hospitalization rate for the entire cohort was 9% and 37%, respectively however, it varied according to the BC disease status. CONCLUSIONS: Using one of the largest registries on cancer and COVID-19, we identified patient and BC-related factors associated with worse COVID-19 outcomes. After adjusting for baseline characteristics, underrepresented racial/ethnic patients experienced worse outcomes compared to non-Hispanic White patients. FUNDING: This study was partly supported by National Cancer Institute grant number P30 CA068485 to Tianyi Sun, Sanjay Mishra, Benjamin French, Jeremy L Warner; P30-CA046592 to Christopher R Friese; P30 CA023100 for Rana R McKay; P30-CA054174 for Pankil K Shah and Dimpy P Shah; KL2 TR002646 for Pankil Shah and the American Cancer Society and Hope Foundation for Cancer Research (MRSG-16-152-01-CCE) and P30-CA054174 for Dimpy P Shah. REDCap is developed and supported by Vanderbilt Institute for Clinical and Translational Research grant support (UL1 TR000445 from NCATS/NIH). The funding sources had no role in the writing of the manuscript or the decision to submit it for publication. CLINICAL TRIAL NUMBER: CCC19 registry is registered on ClinicalTrials.gov, NCT04354701

Are mycotoxins relevant to be studied in health care environments?

Project EXPOsE, nº 23222 (02/SAICT/2016)Mycotoxins are fungi metabolites produced by specific fungal genera and although the reported evidence about the health effects there is still a gap about data in health care environments. This study aimed to investigate if mycotoxins presence should be monitored in health care facilities by searching for studies that reported fungal contamination by toxigenic fungi in different health care environments. The study involved a systematic search of available information/data published on PubMed during the period of 2010 until 31st December 2018. Among the 26 papers analyzed, only in two the Aspergillus genera were not reported as the most prevalent. Additionally, other genera also with toxigenic potential were observed, namely Fusarium and Penicillium. The information gathered with this review allowed to conclude about the importance to assess mycotoxins in health care environments. Moreover, the analytical methods used should allow detecting low concentrations and multiple mycotoxins.info:eu-repo/semantics/publishedVersio